Garnet Equity Capital Holdings Inc. Makes New $7.06 Million Investment in Establishment Labs Holdings Inc. $ESTA

Garnet Equity Capital Holdings Inc. bought a new stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 165,339 shares of the company’s stock, valued at approximately $7,062,000. Establishment Labs makes up approximately 1.7% of Garnet Equity Capital Holdings Inc.’s holdings, making the stock its 15th largest holding. Garnet Equity Capital Holdings Inc. owned approximately 0.57% of Establishment Labs at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the business. Geode Capital Management LLC raised its holdings in shares of Establishment Labs by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock worth $1,105,000 after acquiring an additional 299 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its stake in Establishment Labs by 5.2% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 6,025 shares of the company’s stock valued at $257,000 after purchasing an additional 300 shares during the last quarter. Raymond James Financial Inc. raised its stake in shares of Establishment Labs by 0.4% in the first quarter. Raymond James Financial Inc. now owns 119,752 shares of the company’s stock worth $4,886,000 after purchasing an additional 491 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Establishment Labs by 1.3% in the first quarter. Swiss National Bank now owns 39,000 shares of the company’s stock valued at $1,591,000 after purchasing an additional 500 shares in the last quarter. Finally, CWM LLC boosted its position in shares of Establishment Labs by 45.9% during the second quarter. CWM LLC now owns 2,182 shares of the company’s stock valued at $93,000 after buying an additional 686 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ESTA. Mizuho lifted their price objective on shares of Establishment Labs from $70.00 to $85.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Wall Street Zen raised shares of Establishment Labs from a “sell” rating to a “hold” rating in a research report on Sunday, October 19th. Citigroup reaffirmed a “neutral” rating on shares of Establishment Labs in a report on Tuesday, October 7th. Needham & Company LLC boosted their price objective on Establishment Labs from $48.00 to $70.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Finally, BTIG Research raised their target price on Establishment Labs from $62.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $66.71.

Establishment Labs Stock Performance

Shares of ESTA stock opened at $63.64 on Thursday. The firm’s 50 day moving average is $45.72 and its 200 day moving average is $41.25. The stock has a market capitalization of $1.85 billion, a P/E ratio of -22.39 and a beta of 0.98. Establishment Labs Holdings Inc. has a 12 month low of $26.56 and a 12 month high of $69.00. The company has a current ratio of 3.33, a quick ratio of 1.67 and a debt-to-equity ratio of 15.06.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.16. The business had revenue of $53.78 million during the quarter, compared to analyst estimates of $52.28 million. Establishment Labs had a negative net margin of 43.45% and a negative return on equity of 235.45%. Establishment Labs’s revenue was up 33.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.59) EPS. Establishment Labs has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Establishment Labs Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.